Loading
The trial that showed Hansoh's aumolertinib roughly doubles progression-free survival compared with gefitinib in EGFR-mutant lung cancer.
429 patients, double blind. Median progression-free survival 19.3 versus 9.9 months (hazard ratio 0.46), consistent across exon 19 and L858R subgroups and in patients with brain metastases; published in the Journal of Clinical Oncology 2022. NMPA first-line approval December 2021. Aumolertinib has since become one of the most prescribed targeted drugs in China.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares FURLONG, EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares FURLONG and the tag china.
Shares Non-small-cell lung cancer and the tag china.
Shares EGFR, Non-small-cell lung cancer and the tag china.
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag china.